Novartis announced the acquisition of Selexys Pharmaceuticals; the deal comes as a consequence of the positive results obtained during the SUSTAIN study, a phase 2 trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD). This hereditary blood disorder is characterized by sickle-shaped red blood cells and it represents a life-long disease with many forms that can range in clinical severity from asymptomatic to life-threatening. “Sickle cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease,” said Bruno Strigini, CEO of Novartis Oncology.
“With this acquisition, Novartis is able to leverage its leadership in haematology research to advance development of a potential new treatment option for patients living with this debilitating condition.” Terms of the deal could total up to $665 million in upfront, acquisition and milestone payments.